259 related articles for article (PubMed ID: 24862395)
1. Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer.
Ankerst DP; Hoefler J; Bock S; Goodman PJ; Vickers A; Hernandez J; Sokoll LJ; Sanda MG; Wei JT; Leach RJ; Thompson IM
Urology; 2014 Jun; 83(6):1362-7. PubMed ID: 24862395
[TBL] [Abstract][Full Text] [Related]
2. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
[TBL] [Abstract][Full Text] [Related]
3. The prostate cancer risk calculator from the Prostate Cancer Prevention Trial underestimates the risk of high grade cancer in contemporary referral patients.
Ngo TC; Turnbull BB; Lavori PW; Presti JC
J Urol; 2011 Feb; 185(2):483-7. PubMed ID: 21167519
[TBL] [Abstract][Full Text] [Related]
4. The impact of prostate volume, number of biopsy cores and American Urological Association symptom score on the sensitivity of cancer detection using the Prostate Cancer Prevention Trial risk calculator.
Ankerst DP; Till C; Boeck A; Goodman P; Tangen CM; Feng Z; Partin AW; Chan DW; Sokoll L; Kagan J; Wei JT; Thompson IM
J Urol; 2013 Jul; 190(1):70-6. PubMed ID: 23313212
[TBL] [Abstract][Full Text] [Related]
5. A Contemporary Prostate Biopsy Risk Calculator Based on Multiple Heterogeneous Cohorts.
Ankerst DP; Straubinger J; Selig K; Guerrios L; De Hoedt A; Hernandez J; Liss MA; Leach RJ; Freedland SJ; Kattan MW; Nam R; Haese A; Montorsi F; Boorjian SA; Cooperberg MR; Poyet C; Vertosick E; Vickers AJ
Eur Urol; 2018 Aug; 74(2):197-203. PubMed ID: 29778349
[TBL] [Abstract][Full Text] [Related]
6. Prostate cancer risk prediction in a urology clinic in Mexico.
Liang Y; Messer JC; Louden C; Jimenez-Rios MA; Thompson IM; Camarena-Reynoso HR
Urol Oncol; 2013 Oct; 31(7):1085-92. PubMed ID: 22306115
[TBL] [Abstract][Full Text] [Related]
7. Predicting the outcome of prostate biopsy: comparison of a novel logistic regression-based model, the prostate cancer risk calculator, and prostate-specific antigen level alone.
Hernandez DJ; Han M; Humphreys EB; Mangold LA; Taneja SS; Childs SJ; Bartsch G; Partin AW
BJU Int; 2009 Mar; 103(5):609-14. PubMed ID: 19007374
[TBL] [Abstract][Full Text] [Related]
8. Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial.
Thompson IM; Pauler Ankerst D; Chi C; Goodman PJ; Tangen CM; Lippman SM; Lucia MS; Parnes HL; Coltman CA
J Clin Oncol; 2007 Jul; 25(21):3076-81. PubMed ID: 17634486
[TBL] [Abstract][Full Text] [Related]
9. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial.
Thompson IM; Ankerst DP; Chi C; Goodman PJ; Tangen CM; Lucia MS; Feng Z; Parnes HL; Coltman CA
J Natl Cancer Inst; 2006 Apr; 98(8):529-34. PubMed ID: 16622122
[TBL] [Abstract][Full Text] [Related]
10. Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group.
Ankerst DP; Boeck A; Freedland SJ; Thompson IM; Cronin AM; Roobol MJ; Hugosson J; Stephen Jones J; Kattan MW; Klein EA; Hamdy F; Neal D; Donovan J; Parekh DJ; Klocker H; Horninger W; Benchikh A; Salama G; Villers A; Moreira DM; Schröder FH; Lilja H; Vickers AJ
World J Urol; 2012 Apr; 30(2):181-7. PubMed ID: 22210512
[TBL] [Abstract][Full Text] [Related]
11. [Comparison of two on-line risk calculators versus the detection of circulating prostate cells for the detection of high risk prostate cancer at first biopsy.].
Murray NP; Fuentealba C; Reyes E; Jacob O
Arch Esp Urol; 2017 Jun; 70(5):503-512. PubMed ID: 28613202
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Prostate Cancer Risk Calculators for Shared Decision Making Across Diverse Urology Practices in Michigan.
Auffenberg GB; Merdan S; Miller DC; Singh K; Stockton BR; Ghani KR; Denton BT
Urology; 2017 Jun; 104():137-142. PubMed ID: 28237530
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancers diagnosed at repeat biopsy are smaller and less likely to be high grade.
Tan N; Lane BR; Li J; Moussa AS; Soriano M; Jones JS
J Urol; 2008 Oct; 180(4):1325-9; discussion 1329. PubMed ID: 18707706
[TBL] [Abstract][Full Text] [Related]
14. Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator.
Ankerst DP; Goros M; Tomlins SA; Patil D; Feng Z; Wei JT; Sanda MG; Gelfond J; Thompson IM; Leach RJ; Liss MA
Eur Urol Focus; 2019 Jan; 5(1):54-61. PubMed ID: 29422418
[TBL] [Abstract][Full Text] [Related]
15. Prospective development of a prostate cancer risk calculator in a racially diverse population: The Kaiser Permanente Prostate Cancer Risk Calculator.
Presti J; Alexeeff S; Horton B; Prausnitz S; Avins AL
Urol Oncol; 2020 Nov; 38(11):847.e1-847.e8. PubMed ID: 32536468
[TBL] [Abstract][Full Text] [Related]
16. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
Haese A; Dworschack RT; Partin AW
J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298
[TBL] [Abstract][Full Text] [Related]
17. Development and External Validation of the Korean Prostate Cancer Risk Calculator for High-Grade Prostate Cancer: Comparison with Two Western Risk Calculators in an Asian Cohort.
Park JY; Yoon S; Park MS; Choi H; Bae JH; Moon DG; Hong SK; Lee SE; Park C; Byun SS
PLoS One; 2017; 12(1):e0168917. PubMed ID: 28046017
[TBL] [Abstract][Full Text] [Related]
18. PCPT: Evidence that finasteride reduces risk of most frequently detected intermediate- and high-grade (Gleason score 6 and 7) cancer.
Kaplan SA; Roehrborn CG; Meehan AG; Liu KS; Carides AD; Binkowitz BS; Heyden NL; Vaughan ED
Urology; 2009 May; 73(5):935-9. PubMed ID: 19328538
[TBL] [Abstract][Full Text] [Related]
19. Risk score predicts high-grade prostate cancer in DNA-methylation positive, histopathologically negative biopsies.
Van Neste L; Partin AW; Stewart GD; Epstein JI; Harrison DJ; Van Criekinge W
Prostate; 2016 Sep; 76(12):1078-87. PubMed ID: 27121847
[TBL] [Abstract][Full Text] [Related]
20. Negative Prebiopsy Magnetic Resonance Imaging and Risk of Significant Prostate Cancer: Baseline and Long-Term Followup Results.
Buisset J; Norris JM; Puech P; Leroy X; Ramdane N; Drumez E; Villers A; Olivier J
J Urol; 2021 Mar; 205(3):725-731. PubMed ID: 33080153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
